Holen Sie sich die Stockscreener-App
90.18
1.68%
1.49
Handel nachbörslich:
90.18
Schlusskurs vom Vortag:
$88.69
Offen:
$88.43
24-Stunden-Volumen:
622.09K
Relative Volume:
1.04
Marktkapitalisierung:
$5.65B
Einnahmen:
$434.41M
Nettoeinkommen (Verlust:
$-128.05M
KGV:
-9.8128
EPS:
-9.19
Netto-Cashflow:
$-250.52M
1W Leistung:
-9.70%
1M Leistung:
+4.86%
6M Leistung:
-14.08%
1J Leistung:
+41.66%
1-Tages-Spanne:
$88.05
$90.66
1-Wochen-Bereich:
$88.05
$100.85
52-Wochen-Spanne:
$63.50
$121.90
Blueprint Medicines Corp Stock (BPMC) Company Profile
Firmenname
Blueprint Medicines Corp
Sektor
Branche
Telefon
617-374-7580
Adresse
45 SIDNEY STREET, CAMBRIDGE, MA
Vergleichen Sie BPMC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| BPMC | 90.18 | 5.65B | 434.41M | -128.05M | -250.52M | -9.19 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Blueprint Medicines Corp Stock (BPMC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-10-27 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-08-21 | Bestätigt | Needham | Buy |
| 2023-07-31 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-06-05 | Herabstufung | SVB Securities | Market Perform → Underperform |
| 2023-01-03 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | Eingeleitet | Needham | Buy |
| 2022-11-02 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-09-14 | Eingeleitet | Berenberg | Buy |
| 2022-07-08 | Eingeleitet | Oppenheimer | Outperform |
| 2022-06-27 | Eingeleitet | Wells Fargo | Underweight |
| 2022-06-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-06-01 | Hochstufung | Jefferies | Hold → Buy |
| 2022-03-01 | Eingeleitet | Citigroup | Neutral |
| 2022-02-17 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-01-25 | Hochstufung | Stifel | Hold → Buy |
| 2021-11-19 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-09-30 | Fortgesetzt | Stifel | Hold |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-03-31 | Eingeleitet | Credit Suisse | Neutral |
| 2020-12-03 | Eingeleitet | Stifel | Hold |
| 2020-11-02 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-02 | Herabstufung | Jefferies | Buy → Hold |
| 2020-10-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-15 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-05 | Eingeleitet | Barclays | Equal Weight |
| 2020-03-17 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-28 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-27 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2019-11-06 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-10-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2019-10-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-09-12 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-08-29 | Eingeleitet | Piper Jaffray | Neutral |
| 2019-08-15 | Fortgesetzt | Raymond James | Mkt Perform |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Buy |
| 2019-04-03 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-09-25 | Eingeleitet | Leerink Partners | Outperform |
| 2017-12-11 | Bestätigt | Goldman | Buy |
Alle ansehen
Blueprint Medicines Corp Aktie (BPMC) Neueste Nachrichten
Blueprint Medicines (NASDAQ:BPMC) Receives "Market Outperform" Rating from JMP Securities - MarketBeat
Blueprint Medicines’ (BPMC) “Buy” Rating Reiterated at Needham & Company LLC - Defense World
Blueprint Medicines’ (BPMC) Buy Rating Reiterated at HC Wainwright - Defense World
Prime Capital Investment Advisors LLC Sells 6,476 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Sees Large Growth in Short Interest - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Blueprint Medicines (NASDAQ:BPMC) Given Buy Rating at Needham & Company LLC - MarketBeat
HC Wainwright Reiterates Buy Rating for Blueprint Medicines (NASDAQ:BPMC) - MarketBeat
JP Morgan Initiates Coverage of Blueprint Medicines (BPMC) with Overweight Recommendation - MSN
Key Takeaways From Blueprint Medicines Analyst Ratings - Benzinga
Blueprint Medicines (NASDAQ:BPMC) Now Covered by JPMorgan Chase & Co. - MarketBeat
Mastocytosis Treatment Market Forecasted for Major Expansion - openPR
Entropy Technologies LP Takes Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Holdings Raised by US Bancorp DE - MarketBeat
M&G Plc Makes New $9.10 Million Investment in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines (NASDAQ:BPMC) Stock Rating Upgraded by StockNews.com - MarketBeat
Blueprint Medicines' SWOT analysis: stock soars on Ayvakit success, pipeline potential - Investing.com
Blueprint Medicines discloses CDK2 inhibitors for cancer - BioWorld Online
Systemic Mastocytosis Treatment Market to Grow by USD 157.1 Million from 2024-2028, Driven by Aging Population and AI-Redefined Market LandscapeTechnavio - The Malaysian Reserve
Blueprint Medicines (NASDAQ:BPMC) Price Target Lowered to $151.00 at Wells Fargo & Company - Defense World
Q1 Earnings Forecast for BPMC Issued By HC Wainwright - MarketBeat
Emerald Advisers LLC Has $34.77 Million Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines (NASDAQ:BPMC) Given “Buy” Rating at Needham & Company LLC - Defense World
Analysts Have Made A Financial Statement On Blueprint Medicines Corporation's (NASDAQ:BPMC) Third-Quarter Report - Yahoo Finance
Blueprint Medicines Third Quarter 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Q4 EPS Estimates for Blueprint Medicines Boosted by Wedbush - MarketBeat
Earnings call: Blueprint Medicines sees revenue soar with AYVAKIT sales By Investing.com - Investing.com South Africa
Earnings call: Blueprint Medicines sees revenue soar with AYVAKIT sales - Investing.com
Blueprint Medicines Corporation (NASDAQ:BPMC) Q3 2024 Earnings Call Transcript - Insider Monkey
Blueprint Medicines stock target upgraded, buy rating on Ayvakit sales - Investing.com
Blueprint Medicines (NASDAQ:BPMC) Receives "Buy" Rating from HC Wainwright - MarketBeat
Blueprint Medicines Corp (BPMC) Q3 2024 Earnings Call Highlights: Record AYVAKIT Revenue and Raised Guidance - GuruFocus.com
Blueprint Medicines Corp (BPMC) Q3 2024 Earnings Call Highlights: Record AYVAKIT Revenue and ... - Yahoo Finance
Blueprint Medicines Reports Strong Q3 2024 Results - TipRanks
Blueprint Medicines Corp earnings beat by $0.07, revenue topped estimates - Investing.com Australia
Blueprint Medicines shares buoyed by Ayvakit sales beat - Investing.com
Blueprint Medicines (NASDAQ:BPMC) Shares Gap UpHere's Why - MarketBeat
Needham & Company LLC Reaffirms "Buy" Rating for Blueprint Medicines (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Canada Finance
Blueprint Medicines: Q3 Earnings Snapshot - Marketscreener.com
Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance - PR Newswire
When Can We Expect A Profit From Blueprint Medicines Corporation (NASDAQ:BPMC)? - Simply Wall St
Assenagon Asset Management S.A. Lowers Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Corporation (NASDAQ:BPMC): Are Analysts Optimistic? - Yahoo Finance UK
UBS Group Initiates Coverage on Blueprint Medicines (NASDAQ:BPMC) - Defense World
Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma - Barchart
Analyst Ratings For Blueprint Medicines - Benzinga
Blueprint Medicines (NASDAQ:BPMC) Receives New Coverage from Analysts at UBS Group - MarketBeat
UBS sees Blueprint Medicines stock fairly valued, cites limited near-term catalysts - Investing.com UK
Blueprint Medicines' SWOT analysis: stock outlook amid strong Ayvakit sales - Investing.com
Blueprint Medicines (BPMC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Finanzdaten der Blueprint Medicines Corp-Aktie (BPMC)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):